Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE B study.
Nom du journal : Eur J Cancer
Année : 2024
Volume : 196
Page de départ : 113420
